Price (delayed)
$10.82
Market cap
$1.27B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.66
Enterprise value
$1.34B
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent
There are no recent dividends present for ARQT.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.